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Abstract 
 
Purpose of review: Globally the number of deaths associated with tuberculosis and HIV co-infection 
remains unacceptably high. We review the evidence around the impact of strengthening the HIV 
treatment cascade in TB patients and explore recent findings about how best to deliver integrated TB-
HIV services. 
     
Recent findings: There is clear evidence that the timely provision of antiretroviral therapy (ART) reduces 
mortality in TB-HIV co-infected adults. Despite this, globally in 2013 only around a third of known HIV-
positive TB cases were treated with ART. Although there is some recent evidence exploring the barriers 
to achieving high coverage of HIV testing and ART initiation in TB patients, our understanding of which 
factors are most important and how best to address these within different health systems remains 
incomplete. There are some examples of good practice in the delivery of integrated TB-HIV services to 
improve the HIV treatment cascade. However, evidence of the impact of such strategies is of relatively 
low quality for informing integrated TB-HIV programming more broadly. In most settings there remain 
barriers to higher-level organizational and functional integration.   
 
Summary: There remains a need for commitment to patient-centred integrated TB-HIV care in countries 
affected by the dual epidemic. There is a need for better quality evidence around how best to deliver 
integrated services to strengthen the HIV treatment cascade in TB patients, both at primary health care 
level and within community settings.    
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Introduction 
In 2013 there were an estimated 1.1 million cases of tuberculosis (TB) disease in people living with 
human immunodeficiency virus (HIV) and 360 000 deaths attributable to HIV-associated TB [1]. Africa is 
home to around four in every five cases of HIV-associated TB disease [1]. Although there is evidence of 
decreasing mortality from HIV-associated TB (reduction by one third in the last decade), the rate of 
mortality decline is slower than for TB in individuals who are HIV negative[1,2].     
 
The main steps in the HIV treatment cascade for TB patients involve diagnosis of HIV infection, linkage to 
care, initiation of co-trimoxazole prophylaxis and antiretroviral therapy (ART), and achieving and 
maintaining viral load suppression (Figure 1)[3,4]. Delivery of these services is guided by the World 
Health Organization (WHO) policy on collaborative TB/HIV activities[5]. Most countries with a high 
burden of TB/HIV now have specific policies promoting HIV counselling and testing for those with 
presumptive or confirmed TB; and most now recommend ART for all TB cases regardless of CD4+ cell 
count[6]. Routine TB programme reports indicate that, despite scale-up of collaborative TB/HIV services, 
there is still significant attrition along the HIV cascade for TB patients. In 2013 only 48% of TB cases 
notified globally had a documented HIV test result; and of those known to be HIV positive only 70% 
were started on ART (Figure 2)[1]. This suggests that overall only around a third of HIV-positive TB cases 
were treated with antiretroviral therapy. Even these figures mask the fact that three million TB cases are 
estimated to be undiagnosed each year and do not enter the cascade, many of whom are likely to have 
HIV-associated TB[1,7].  
 
Strengthening the HIV treatment cascade is important to reduce the number of deaths from HIV-
associated TB. There is quite significant heterogeneity between countries in the key measures of HIV 
testing and ART initiation for TB patients (Tables 1 & 2). These differences highlight that a one size fits all 
approach to strengthening the cascade may not be appropriate. There do continue to be issues about 
the quality of routine programme data, which are emphasized in the context of TB/HIV where there may 
be discrepancies in reporting the same indicator by TB and HIV programmes[1]. Caution is therefore 
required when interpreting routine aggregated national data alongside data collected in research 
settings or well-defined implementation projects.      
 
This review will summarise recent data that provide insight into the cascade in different settings, with a 
particular focus on evidence around interventions to strengthen the cascade and more broadly to 
support the delivery of integrated TB/HIV services. 
  
HIV testing for TB patients 
There was quite substantial variation globally in the proportion of TB cases with known HIV status in 
2013 – highest in the WHO African region at 76% and below 50% in South-East Asia, Western Pacific, 
and Eastern Mediterranean regions[1]. Even within these regions there is considerable heterogeneity in 
performance between countries (Table 1)[8].  
 
There are several recent examples of good performance in different high burden TB/HIV countries. In 
South Africa, individual reports have confirmed the high national-level uptake of HIV testing and have 
shown that high uptake (>90%) can be achieved in primary health care facilities regardless of the level of 
integration of TB and HIV services[9]; and in drug-resistant TB services regardless of whether centralised 
or decentralised[10]. Although the overall proportion of TB patients tested for HIV in India is low, one 
study described new referral pathways for TB patients in Delhi, allowing direct referral to ART centres 
rather than first sending patients to separate HIV counselling and testing sites. Over the 9-month period 
following implementation, 92% of TB patients received HIV counselling and testing and, of those that 
tested positive, 93% engaged in care [11*]. More broadly in India, there have been concerted efforts to 
scale up an intensified package of collaborative TB/HIV activities facilitated by a joint national TB/HIV 
policy[12*]. Co-location of TB and HIV testing facilities in India has been shown to increase HIV testing 
coverage and is now a priority intervention within the national strategic plan[12*].  
 
Despite calls to move testing upstream and to ensure that all people investigated for TB are offered HIV 
testing[5,13], there is a scarcity of data to show to what extent programmes are achieving this. There 
are also few data describing HIV testing for children undergoing investigation and treatment for TB 
disease. National-level data in South Africa showed some evidence of recent programmatic 
improvement, with the proportion of child TB cases (under 15 years) reported to have unknown HIV 
status declining from 77% to 25% between 2008 and 2012[14].     
 
In order to optimize the uptake of HIV testing, there is a need to better understand the factors behind 
TB patients not being tested for HIV. In terms of patient-level factors, it would be interesting to know 
whether or not there are issues particular to TB patients that could potentially be addressed with 
improved counselling or other specific interventions. One study from Ethiopia, with a high uptake of HIV 
testing among TB patients (92%), suggested that patient-level barriers were not issues specific to TB/HIV 
but rather general factors, such as lack of formal education and lower levels of knowledge about HIV 
[15*].  
 
In general, however, other than co-location of services there is a lack of high quality evidence around 
interventions to maximise uptake of HIV testing in TB patients. Although there are several reports of 
high uptake of HIV testing in various settings, in themselves these may have limited impact as there is 
often no clear evidence of what precisely has contributed to high uptake.  
 
Uptake and timing of antiretroviral therapy for TB patients 
Since 2010, World Health Organization (WHO) guidelines have recommended that all HIV-positive TB 
patients should be commenced on antiretroviral therapy (ART), regardless of CD4+ cell count[16,17]. 
Despite this, coverage of ART in TB patients remains suboptimal – globally in 2013 only 70% of known 
HIV-positive TB patients were commenced on ART prior to or during TB treatment[1].  
 
There is high quality evidence from randomised controlled trials (RCT) that the initiation of ART during 
TB treatment improves survival in HIV-positive TB patients [18-21]. A recent meta-analysis of 12 
observational studies supported this, finding that the use of ART led to a reduction in mortality during 
TB treatment of between 44% and 72% [22*]. There is also recent evidence that confirms that ART 
substantially improves survival for patients with multidrug-resistant and extensively drug-resistant 
TB[23*,24*].  
 
Observational data from Cape Town has confirmed earlier findings from the RCTs that the impact of ART 
is most pronounced amongst patients with low CD4+ cell counts (<350 cells per µL)[25**]. In view of 
this, some continue to question the benefits of ART during TB treatment in patients with higher CD4+ 
cell counts. A recent multi-centre RCT in Africa reported that, for HIV-positive TB patients with CD4+ cell 
count ≥220 cells per µL, there was no difference in the composite endpoint of tuberculosis treatment 
failure, tuberculosis recurrence, and death between those randomised to early ART (after two weeks of 
TB treatment) or delayed ART (at the end of six months of TB treatment)[26**]. However, the trial was 
not powered to detect a difference between the arms in mortality alone and overall mortality was low. 
Also the proportion of those allocated to the delayed ART arm that nonetheless initiated ART during TB 
treatment was not reported. There was no evidence of any adverse effect of early ART and therefore 
this evidence does not support any change in treatment guidelines. 
 
In terms of the timing of ART initiation, a meta-analysis of six RCT demonstrated that early ART initiation 
(within 4 weeks of starting TB treatment) was associated with a reduction in mortality of 25% compared 
to later initiation of ART (8-12 weeks after starting TB treatment)[27]. A post hoc analysis of the 
CAMELIA RCT in Cambodia showed that, compared to early ART (after two weeks of TB treatment), late 
ART (after eight weeks of TB treatment) was associated with more than double the risk of late mortality 
(after week 50), suggesting a long-lasting benefit of early ART among patients with advanced 
immunodeficiency [28*]. A recent RCT from Ethiopia explored the impact of even earlier initiation of 
ART (one week after starting TB treatment, compared to four or eight weeks)[29]. There was no 
evidence that starting ART after one week of TB treatment reduced mortality for all patients, or 
specifically for those with most advanced immunosuppression (CD4+ cell count <50 cells per µL).   
 
Interventions to improve uptake of ART might include integration and decentralization of TB and HIV 
services, and task shifting with nurse-initiated ART. A systematic review explored whether providing ART 
at the TB health facility improves uptake of ART, compared to systems where patients were referred to a 
separate facility[30]. This review of 12 studies, all but one from Africa, suggested that integration 
improved ART coverage (relative risk (RR) 1.83, 95% confidence interval (CI) 1.48-2.25). There was also 
weak evidence that integrated services led to a reduction in mortality amongst HIV/TB patients (RR 0.55, 
95% CI 0.29-1.05)[30].  
 
The Integrating Tuberculosis and Anti-Retroviral Treatment (ITART) study was a prospective cohort study 
in five primary health care clinics in the Democratic Republic of Congo. This study explored outcomes 
with nurse-delivered decentralised and integrated TB/HIV care and compared this to a historical cohort 
where TB patients were referred to a centralised facility for ART initiation[31**].  ART uptake was 69% in 
the integrated TB/HIV model, compared to 17% in the historical cohort. Mortality during TB treatment 
was also lower with the integrated TB/HIV model (10% vs. 20% in the historical cohort)[31**]. Further 
analyses of the ITART study uncovered delays in initiating ART with the integrated TB/HIV care 
model[32*]. For this analysis, delayed ART for TB patients was defined quite tightly as more than five 
days beyond the 1, 2 or 6 month threshold for ART (depending on CD4+ cell count). Overall almost half 
of all patients experienced delayed ART initiation or did not initiate ART at all – delay was particularly 
high (59%) for those that should have started ART within one month (CD4+ cell count <100 cells per µl or 
WHO clinical stage 4). In this analysis, delayed ART was associated with having a contra-indication to at 
least one antiretroviral drug, intolerance to tuberculosis drugs, non-disclosure of HIV status, and lower 
CD4+ cell count[32*]. Modelling of the same data suggested that around a third of the observed 
mortality during the study could have been prevented with perfect fidelity to the recommended timing 
of ART initiation[33**].  
 
Elsewhere, there are other examples where ART coverage has improved with models of integrated 
service delivery. In a before-after study in a regional TB hospital in rural Guatemala, ART uptake 
increased from 22% and 72% and mortality within 50 weeks decreased from an extremely high level of 
78% to 21% with decentralised integrated TB/HIV care[34]. In a before-after study in 17 health facilities 
in western Kenya, integration of TB & HIV services led to an improvement in ART uptake during TB 
treatment from 39% to 61% and a reduction in the median time to ART initiation from 42 days to 34 
days[35]. In Malawi, a before-after study compared ART uptake in an integrated TB/HIV clinic before and 
after the implementation of new guidelines recommending ART within two weeks for all TB patients. 
Overall ART uptake improved from 70% to 78% and the proportion starting ART within two weeks 
increased from 30% to 46%[36*]. 
 
Although studies consistently demonstrate that a significant number of TB patients do not start ART, 
there is relatively limited understanding about the factors that contribute to this. One qualitative study 
in the Kingdom of Swaziland involved in-depth interviews with HIV-positive TB patients that had not 
initiated ART[37*]. This highlighted factors operating at an individual level, such as concern about 
medication side-effects and pill burden as well as deeper issues such as lack of readiness for lifelong 
treatment. However, the interviews also uncovered important health system barriers, such as poor 
relationships with clinic staff, failure to receive adequate counselling, and limited availability of 
diagnostic tests[37*]. In Namibia, health care workers also identified significant structural barriers to 
ART initiation for TB patients, most notably human resource shortages, lack of training, and lack of 
physical space in which to provide care[38]. Even in an inpatient setting in Tanzania, significant health 
system barriers to TB/HIV integration were identified by health care workers.[39]   
 
Data on uptake and timing of ART initiation for children with TB disease are particularly scarce. In the 
ITART study, 30 ART-naïve children aged 3-18 years were included. Overall, 73% initiated ART either 
during TB treatment or on completion of TB treatment yet in some cases, similarly to the adults in the 
same study, there were significant delays in starting ART[40].   
 
Viral suppression for TB patients on antiretroviral therapy  
With the potential for drug-drug interactions, drug toxicity and challenges to adherence with combined 
TB treatment and ART, it is important to understand whether virologic outcomes are compromised by 
concurrent TB treatment. A systematic review of 17 studies found no evidence of a difference in 
virologic suppression between those on TB treatment and those not on TB treatment at the time of ART 
initiation[41*]. Overall, the random-effects relative risk for virologic suppression at 11-12 months was 
0.99 (95% confidence interval 0.94-1.05). In a recent single study in five Ethiopian health centres, the 
overall proportion with virologic suppression (<50 copies/mL) at six months was similar for participants 
with and without concurrent TB at the time of ART initiation (71% vs. 72%, p=0.74)[42]. In patients 
unable to tolerate efavirenz in first-line ART, nevirapine remains an option in the absence of alternative 
drugs, although efavirenz-based ART is associated with superior rates of virological suppression when 
co-administered with TB treatment [43]. 
 
There are specific issues with combined TB treatment and ART in children, particularly young children 
using protease inhibitors. In a large hospital programme in South Africa, 92 of 199 children aged 0-8 
years were on TB treatment at the time of ART initiation. Overall, TB treatment did not affect the 
likelihood of achieving virological suppression (proportion with viral load <50 copies/ml at 12 months 
63% for TB patients vs. 62% for those without TB) or of experiencing viral rebound over 24 months of 
follow-up[44*].  
 
Models of TB & HIV service integration 
Integration of TB/HIV services is aimed at improving the efficiency and effectiveness of the health 
system and reducing opportunities for attrition in the cascade of care[45**]. It is not clear how 
integration should be measured, although attempts have been made to develop instruments capable of 
determining the extent of clinical and organizational integration[45**]. This tool was used evaluate the 
impact of integration on clinical outcomes in 33 clinics within Cape Town. There was some evidence 
that, after adjusting for individual-level and clinic-level factors, two of the derived domains of TB/HIV 
integration (integrated service delivery and care provided by the same clinician) were associated with 
lower mortality[46*].  
There is a paucity of evidence around how different models of TB/HIV integration might influence 
retention in care and viral suppression. Encouragingly, two ongoing clinical trials are exploring models of 
integrated TB/HIV care and the impact on retention in care [47,48]. In the MERGE cluster randomised 
trial in South Africa, the intervention being studied is a set of clinic-specific activities to optimize 
integration of TB and HIV services [47]. The Start TB Patients on ART and Retain on Treatment (START 
Study) in Lesotho is testing a multifaceted intervention package incorporated into integrated HIV/TB 
care – nurse training and clinical mentoring as well as support for patients (health education, adherence 
support, and financial support) [48].  
Integration of TB and HIV services can encompass different models and the organisation and delivery of 
services needs to be context specific and focused on the needs of patients, families and communities. 
Co-location of services within health facilities in itself does not necessarily meet the needs of patients if 
service delivery remains fragmented[45]. As the delivery of HIV treatment and care is increasingly 
decentralised and moved out of health facilities into the community, there is a need for research into 
community-based integrated models of TB/HIV care [49, 50*, 51]. Most of the published evidence about 
integration focuses on clinical integration, yet there remain significant barriers to higher-level 
organizational or functional integration of programmes within the broader health system[45,52**]. In 
most settings, HIV and TB programmes remain vertical programmes with separate organizational 
structures, separate policies and guidelines, separate budgeting, and separate monitoring and 
evaluation systems. There are often historical and cultural differences between TB and HIV programmes 
that provide challenges to integration[53*,54]. In many countries, HIV and TB programmes are also 
dependent on funding from international donors and may be somewhat restricted in how services can 
be developed. Encouragingly, the Global Fund now stipulates that the 41 countries with a high burden of 
TB-HIV co-infection should submit applications that encompass integrated and joint programming for 
the two diseases[55].  
Conclusions 
For TB patients globally, considerable progress will be needed to achieve the UNAIDS 90-90-90 targets 
by 2020. Strengthening of the HIV treatment cascade for TB patients needs to be coordinated with 
initiatives to find undiagnosed TB/HIV cases within the health system and more broadly in the 
community. There is a need for higher quality evidence, combined with economic analysis, to inform the 
scale-up of efficient TB/HIV services in different settings.   
  
Key points 
 Only around a third of HIV-positive TB patients currently receive antiretroviral therapy, highlighting 
a significant gap between evidence and impact  
 Scale-up of collaborative TB/HIV services has improved coverage of HIV testing and uptake of 
antiretroviral therapy, particularly in some countries with the highest burden of HIV-associated TB 
 Significant barriers to TB/HIV integration exist at all levels of the health system and there is a paucity 
of evidence around how to improve integration 
 Targeted measures to strengthen the HIV treatment cascade for TB patients may be necessary 
within the framework of broader health system strengthening but this should be combined with 
strategies to find people with undiagnosed TB/HIV   
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Figure titles and legends 
 
Figure 1 The HIV treatment cascade in TB patients and indicators used to evaluate the cascade  
 
Figure 2 Cascade graph of diagnosis and treatment of HIV in TB cases, 2013 (global data) [1] 
